The adenosinergic system in cancer: Key therapeutic target

High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as well as on the receptor subtypes that are expressed by immune cells, adenosine can affect tumor growth in different fashions. Specifically targeting CD73, the rate-limiting enzyme for the extracellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorrentino, Rosalinda, Pinto, Aldo, Morello, Silvana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583919/
https://www.ncbi.nlm.nih.gov/pubmed/23483072
http://dx.doi.org/10.4161/onci.22448
_version_ 1782475506373885952
author Sorrentino, Rosalinda
Pinto, Aldo
Morello, Silvana
author_facet Sorrentino, Rosalinda
Pinto, Aldo
Morello, Silvana
author_sort Sorrentino, Rosalinda
collection PubMed
description High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as well as on the receptor subtypes that are expressed by immune cells, adenosine can affect tumor growth in different fashions. Specifically targeting CD73, the rate-limiting enzyme for the extracellular generation of adenosine, or the A3 receptor offers new therapeutic strategies to limit tumor progression.
format Online
Article
Text
id pubmed-3583919
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35839192013-03-11 The adenosinergic system in cancer: Key therapeutic target Sorrentino, Rosalinda Pinto, Aldo Morello, Silvana Oncoimmunology Author's View High amounts of adenosine are released in the tumor mass. Depending on the levels of adenosine, as well as on the receptor subtypes that are expressed by immune cells, adenosine can affect tumor growth in different fashions. Specifically targeting CD73, the rate-limiting enzyme for the extracellular generation of adenosine, or the A3 receptor offers new therapeutic strategies to limit tumor progression. Landes Bioscience 2013-01-01 /pmc/articles/PMC3583919/ /pubmed/23483072 http://dx.doi.org/10.4161/onci.22448 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Sorrentino, Rosalinda
Pinto, Aldo
Morello, Silvana
The adenosinergic system in cancer: Key therapeutic target
title The adenosinergic system in cancer: Key therapeutic target
title_full The adenosinergic system in cancer: Key therapeutic target
title_fullStr The adenosinergic system in cancer: Key therapeutic target
title_full_unstemmed The adenosinergic system in cancer: Key therapeutic target
title_short The adenosinergic system in cancer: Key therapeutic target
title_sort adenosinergic system in cancer: key therapeutic target
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583919/
https://www.ncbi.nlm.nih.gov/pubmed/23483072
http://dx.doi.org/10.4161/onci.22448
work_keys_str_mv AT sorrentinorosalinda theadenosinergicsystemincancerkeytherapeutictarget
AT pintoaldo theadenosinergicsystemincancerkeytherapeutictarget
AT morellosilvana theadenosinergicsystemincancerkeytherapeutictarget
AT sorrentinorosalinda adenosinergicsystemincancerkeytherapeutictarget
AT pintoaldo adenosinergicsystemincancerkeytherapeutictarget
AT morellosilvana adenosinergicsystemincancerkeytherapeutictarget

Ejemplares similares